Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the PancreasHIDALGO, Manuel; VON HOFF, Daniel D.Clinical cancer research (Print). 2012, Vol 18, Num 16, pp 4249-4256, issn 1078-0432, 8 p.Article

Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cellsHONG WANG; HAIYONG HAN; VON HOFF, Daniel D et al.Cancer research (Baltimore). 2006, Vol 66, Num 19, pp 9722-9730, issn 0008-5472, 9 p.Article

Gemcitabine HCl: combined efficacy and tolerability in managing the solid tumor patientVON HOFF, Daniel D; GREEN, Mark R.Seminars in oncology. 1996, Vol 23, Num 5, issn 0093-7754, 102 p., SUP10Serial Issue

Tubulin-associated drug targets : Aurora kinases, polo-like kinases, and othersWARNER, Steven L; GRAY, Phillip J; VON HOFF, Daniel D et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 436-448, issn 0093-7754, 13 p.Article

Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agentsHONG WANG; HAIYONG HAN; MOUSSES, Spyro et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 513-520, issn 0093-7754, 8 p.Article

Pursuing therapeutic targetsVON HOFF, Daniel D; GRAY, Phillip J; DRAGOVICH, Tomislav et al.Seminars in oncology. 2006, Vol 33, Num 4, issn 0093-7754, 156 p.Serial Issue

Quality of life assessment in chemotherapy trials for non-small cell lung cancer : Are theory and practice significantly different ?HOPWOOD, P.Seminars in oncology. 1996, Vol 23, Num 5, pp 60-64, issn 0093-7754, SUP10Article

Single-agent activity of gemcitabine in advanced non-small cell lung cancerLE CHEVALIER, T.Seminars in oncology. 1996, Vol 23, Num 5, pp 36-42, issn 0093-7754, SUP10Article

Phase I studies with the novel nucleoside analog gemcitabineABBRUZZESE, J. L.Seminars in oncology. 1996, Vol 23, Num 5, pp 25-31, issn 0093-7754, SUP10Article

Gemcitabine safety overviewGREEN, M. R.Seminars in oncology. 1996, Vol 23, Num 5, pp 32-35, issn 0093-7754, SUP10Article

An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancerEVANS, W. K.Seminars in oncology. 1996, Vol 23, Num 5, pp 82-89, issn 0093-7754, SUP10Article

Synergistic Effect between Erlotinib and MEK Inhibitors in KRAS Wild-Type Human Pancreatic Cancer CellsDIEP, Caroline H; MUNOZ, Ruben M; CHOUDHARY, Ashish et al.Clinical cancer research (Print). 2011, Vol 17, Num 9, pp 2744-2756, issn 1078-0432, 13 p.Article

Epidermal growth factor receptor targeting in cancerMENDELSOHN, John; BASELGA, Jose.Seminars in oncology. 2006, Vol 33, Num 4, pp 369-385, issn 0093-7754, 17 p.Article

Heat shock protein 90 : A unique chemotherapeutic targetCULLINAN, Sara B; WHITESELL, Luke.Seminars in oncology. 2006, Vol 33, Num 4, pp 457-465, issn 0093-7754, 9 p.Article

A phase I study of gemcitabine and carboplatin in non-small cell lung cancerCARMICHAEL, J; ALLERHEILIGEN, S; WALLING, J et al.Seminars in oncology. 1996, Vol 23, Num 5, pp 55-59, issn 0093-7754, SUP10Article

Telomere maintenance mechanisms as a target for drug developmentBEARSS, David J; HURLEY, Laurence H; VON HOFF, Daniel D et al.Oncogene (Basingstoke). 2000, Vol 19, Num 56, pp 6632-6641, issn 0950-9232Article

Phase II activity of gemcitabine in advanced breast cancerCARMICHAEL, J; WALLING, J.Seminars in oncology. 1996, Vol 23, Num 5, pp 77-81, issn 0093-7754, SUP10Article

Novel agents that target tublin and related elementsROWINSKY, Eric K; CALVO, Emiliano.Seminars in oncology. 2006, Vol 33, Num 4, pp 421-435, issn 0093-7754, 15 p.Article

Targeting the Bcl-2 family in cancer therapyPAPADOPOULOS, Kyriakos.Seminars in oncology. 2006, Vol 33, Num 4, pp 449-456, issn 0093-7754, 8 p.Article

Does intraosseous equal intravenous? A pharmacokinetic studyVON HOFF, Daniel D; KUHN PHARM, John G; BURNS, Howard A et al.The American journal of emergency medicine. 2008, Vol 26, Num 1, pp 31-38, issn 0735-6757, 8 p.Article

Gemcitabine in cisplatin-resistant ovarian cancerLUND, B; NEIJT, J. P.Seminars in oncology. 1996, Vol 23, Num 5, pp 72-76, issn 0093-7754, SUP10Article

Radiosensitization of human solid tumor cell lines with gemcitabineSHEWACH, D. S; LAWRENCE, T. S.Seminars in oncology. 1996, Vol 23, Num 5, pp 65-71, issn 0093-7754, SUP10Article

Targeting HER2 epitopesSUMANTA KUMAR PAL; PEGRAM, Mark.Seminars in oncology. 2006, Vol 33, Num 4, pp 386-391, issn 0093-7754, 6 p.Article

Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer elementHURLEY, Laurence H; VON HOFF, Daniel D; SIDDIQUI-JAIN, Adam et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 498-512, issn 0093-7754, 15 p.Article

Role of raf kinase in cancer : Therapeutic potential of targeting the raf/MEK/ERK signal transduction pathwayGOLLOB, Jared A; WILHELM, Scott; CARTER, Chris et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 392-406, issn 0093-7754, 15 p.Article